AstraZeneca Secures Permission for Enhanced Use of Enhertu in India for Breast Cancer Treatment
AstraZeneca Pharma India Ltd has received crucial regulatory permission allowing it to market Trastuzumab Deruxtecan under its brand name, Enhertu®, for an additional indication in India. This approval comes from the Central Drugs Standard Control Organization, Directorate General of Health Services, Government of India.The permission specifically covers the import for sale and distribution of Trastuzumab Deruxtecan 100mg/5mL lyophilized powder for concentrate for solution for infusion (Enhertu®). This milestone paves the way for expanding the availability of the drug in the Indian market.
Under this approved indication, Enhertu is designated for the adjuvant treatment of adult patients afflicted with HER2-positive breast cancer who possess residual invasive disease following pre-treatment protocols. These protocols involve neoadjuvant Trastuzumab, which may or may not include Pertuzumab and taxane-based treatment.
The granting of this permission signifies a major step toward making advanced oncology care accessible in India. The marketing of Trastuzumab Deruxtecan 100mg/5mL lyophilized powder for concentrate for solution for infusion (Enhertu®) for the specified additional indication is subject to receipt of any related statutory approvals.
ASTRAZEN Stock Price Movement
On Friday, shares of AstraZeneca Pharma India Limited edged higher, closing at ₹8191 after gaining 1.54%, translating to an increase of ₹124.50 per share. The equity traded on a volume of 2,409 shares, reflecting sustained buying interest in the pharmaceutical sector.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.